Remove 2021 Remove Bipolar disorder Remove Sleep and mental health
article thumbnail

Eyes, Ears, and Emotion: Techniques to Tackle Diagnosing Bipolar Disorder

Psychiatric Times

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. Non-pharmacological approaches and combination therapies are emphasized in treatment, with recent FDA approvals for new medications targeting bipolar symptoms.

52
article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

Related Videos Related Content Advertisement July 7th 2025 The Psychiatric Pipeline in Review: Quarter 2, 2025 Leah Kuntz September 27th 2021 Treating ‘Morally Objectionable’ Patients James L.

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

Ms Barbee has a passion to reduce the stigma around mental health and promoting increased access to mental health care and education of both clinicians and the general public. She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Goldberg, MD, and Anita H.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.